SCHEMBL20340306

SCHEMBL20340306

O=S(=O)(Nc1cc2nsnc2cc1F)c1c[nH]c2c1ccc1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 6/20 0.44
▸ TSHR P16473 1/20 0.43
▸ POLB P06746 2/20 0.35
▸ CTDSP1 Q9GZU7 2/20 0.35
▸ CASP6 P55212 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ CHEK1 O14757 1/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ NEK2 P51955 1/20 0.34
▸ LIMK1 P53667 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ EDNRA P25101 1/20 0.34
▸ ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30286450 1.00 ACLY (0.44) ACLYTSHRPOLBCTDSP1CASP6
SCHEMBL21545860 0.85 ACLY (0.52) ACLYNR3C1CHEK1CDK8NEK2
SCHEMBL29560159 0.85 ACLY (0.52) ACLYNR3C1CHEK1CDK8NEK2
SCHEMBL20355336 0.83 EDNRA (0.52) CTDSP1CASP6MAPTEDNRA
SCHEMBL30286523 0.83 EDNRA (0.52) CTDSP1CASP6MAPTEDNRA
SCHEMBL20355042 0.82 MAPT (0.55) ACLYTSHRPOLBCTDSP1CASP6
SCHEMBL30286476 0.82 MAPT (0.55) ACLYTSHRPOLBCTDSP1CASP6
SCHEMBL30286599 0.80 ACLY (0.40) ACLYTSHRPOLBCTDSP1CASP6
SCHEMBL20354793 0.80 ACLY (0.40) ACLYTSHRPOLBCTDSP1CASP6
SCHEMBL20355281 0.79 ACLY (0.43) ACLYTSHRPOLBLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 — — US claimed
CN-110121499-B (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides 优时比制药有限公司 2022-12-20 — — CN claimed
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2022-05-31 — — US claimed
US-20220048858-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-02-17 — — US claimed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US claimed
EP-3562820-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB Pharma GmbH (DE) 2019-11-06 — — EP claimed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO claimed
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 — — US disclosed
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-04-28 — — US disclosed
US-20220048858-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2022-02-17 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2019-11-14 — — US disclosed
EP-3562820-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB Pharma GmbH (DE) 2019-11-06 — — EP disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO disclosed
WO-2018122232-A1 (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES UCB PHARMA GMBH (DE) 2018-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127227-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-11345662-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-20220048858-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885
US-20190345104-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 ACLY 3879/4885TSHR 2860/4885POLB 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback